Comparative bioavailability of two different rectal preparations of piroxicam in man
Tóm tắt
A comparative pharmacokinetic study was performed with two types of suppository each containing 20 mg piroxicam. The bioavailability of piroxicam was studied in 24 healthy volunteers in a double blind, randomised, cross over study. No significant difference was found in the pharmacokinetic parameters [AUC(0–72 h), AUC, Cmax, t1/2β calculated from plasma concentration time curves, indicating that the two preparations were bioequivalent.
Tài liệu tham khảo
Lombardino JG, Wiseman EH, Chiaini I (1973) Potent antiinflammatory N-heterocyclic 3-carboxamides of 4-hydroxy-2-methyl-2H-1,2-benzothiazine 1,1-dioxide. J Med Chem 16: 493–496
Wiseman EH, Chang YH, Lombardino JG (1976) Piroxicam, a novel anti-inflammatory agent. Arzneim/Forsch 26: 1300–1303
Otterness IG, Wiseman EH, Gans DJ (1977) Piroxicam. Agents Actions 9: 177–182
Brogden RN, Pinder RM, Speight TM (1977) Piroxicam; a review of its pharmacological properties and therapeutic efficacy. Drugs 22: 165–187
Hobbs DC (1983) Pharmacokinetics of piroxicam in man. Eur J Rheum Inflam 6: 46–55
Schiantarelli P, Acerbi D, Bovis G (1981) Some pharmacokinetic properties and bioavailability by oral and rectal route of piroxicam and rodents and in man. Arzneim Forsch 31: 92–98
Skreblin M, Alebic-Kolbah T, Hofman H (1987) Piroxicam bioavailability by rectal application of Felden and Luber, and oral application of Lubor. Acta Pharm Jugosl 37: 361–369
Hobbs DC, Twomey TM (1979) Piroxicam pharmacokinetics in man: aspirin and antacid interaction studies. J Clin Pharmacol 19: 270–281
Macek J, Vacha J (1987) Rapid and sensitive method for determination of piroxicam in human plasma by high-performance liquid chromatography. J Chromatogr 420: 445–449
Acerbi D, Dacco L, Palummeri E (1983) Pharmacokinetic study of piroxicam after p. o. and rectal administration. Boll Chim Farm 122 [Suppl] 19–27
Ishizaki T, Nomura T, Abe T (1979) Pharmacokinetics of piroxicam, a new nonsteroidal, anti-inflammatory agent, under fasting and postprandial states in man. J Pharmacokinet Biopharm 7: 369–381
Rogers HJ, Savitshy IP, Glenn B (1981) Kinetics of single doses of fenbufen in patients with renal sufficience. Clin Pharmacol Ther 29: 74–80
Brogden RN, Heel RC, Speight TM, Avery GS (1981) Fenbufen: a review of its pharmacological properties and therapeutic use in rheumatic diseases and acute pain. Drugs 21: 1–22
Lombardino JG, Wiseman EH, Otterness IG (1975) Acidic antiinflammatory agents -correlations of some physical, pharmacological and clinical data. Arzneim Forsch 25: 1629–1634
Twomey TM, Hobbs DC (1978) Biotransformation of piroxicam by man. Fed Proc 37: 271–275
Twomey TM, Bartolucci SE, Hobbs DC (1980) Analysis of piroxicam in plasma by high-performance liquid chromatography. J Chromatogr 183: 104–108
Benkő-Márkus S, Grézal Gy, Nagy É, Klebovich I (1991) Comparative pharmacokinetic and bioequivalence studies. (in Hungarian) Gyógyszerészet 35: 479–481
Schuirmann DJ (1987) A comparison of the two one-sided test procedure and the power approach for assesing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15: 657–680
Westlake WJ (1976) Symmetrical confidence intervals for bioequivalence trials. Biometrics 32: 741–744
Westlake WJ (1978) Table to facilitate determination of symmetrical confidence intervals in bioavailability trials with Westlake's method. Eur J Drug Metab Pharmacokinet 2: 129–132
Hauck WW, Anderson S (1984) A new statistical procedure for testing equivalence in two-group comparative bioavailability trials. J Pharmacokinet Biopharm 12: 83–91
Svåb J (1981) Biometrical methods in the research. Mezőgazdasági Kiadó, Budapest (in Hungarian)
Pabst G, Jaeger H (1990) Review of methods and criteria for evaluation of bioequivalence studies. Eur J Clin Pharmacol 38: 5–10